AN2 Therapeutics (ANTX) Current Leases (2022 - 2023)
AN2 Therapeutics (ANTX) reported Current Leases of $13000.0 for Q2 2023, little changed year-over-year from $13000.0 in Q2 2022, and down 61.76% quarter-over-quarter from $34000.0 in Q1 2023.
AN2 Therapeutics (ANTX) Current Leases (2022 - 2023) Analysis & Trends
AN2 Therapeutics (ANTX) has 2 years of Current Leases data on file, last reported at $13000.0 in Q2 2023.
- Current Leases for Q2 2023 came in at $13000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Jun 2023 was $13000.0 (changed 0.0% YoY), and the FY2022 annual result was $53000.0, changed N/A from the prior year.
- Current Leases retreated to $13000.0 in Q2 2023 per ANTX's latest filing, from $34000.0 in the prior quarter.
- Over five years, Current Leases peaked at $73000.0 in Q3 2022 and troughed at $13000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 13,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Sep 30, 2022 | 73,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | 32,000.00 |